I-Mab Inc. - IMAB Enterprise Value-to-Sales Ratio

Official company branding of I-Mab Biopharma Co., Ltd. (IMAB)

The EV/Sales valuation, as shown in this chart on GURU.Markets, demonstrates the business value-to-sales dynamics, where is recorded as the baseline value. I-Mab is building a global oncology network by combining its own biologics with international expertise. The development of targeted antibodies creates a long-term technological foundation for profit. The specifics of the medical sector guarantee capital stability regardless of macroeconomic fluctuations.

I-Mab Biopharma (IMAB): Company Value to Revenue from 07/04/2022 to 11/20/2026

I-Mab Biopharma - analytical breakdowns and key metrics (IMAB)

Fundamental company valuation:IMAB, I-Mab Inc.
Manufactured products of i-mabbiopharma.com

The EV/Sales metric determines the enterprise value of the business relative to generated revenue. For I-Mab (IMAB), this indicator reflects the efficiency of capitalizing innovations in immuno-oncology. By analyzing the current EV/Sales level, an investor identifies valuation deviations from historical averages. This is critical given the massive R&D expenditures required for antibody development. The indicator's range confirms the fundamental stability of the asset.

Competitor analysis